Quick Facts: Uses of Dexne Oftalmico

• Addresses: Ocular inflammatory conditions that respond to a steroid treatment.
• Manages: Inflammation in the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
• Indicated for: Scenarios where a bacterial infection or a risk of bacterial ocular infection is present.

---

Dexne Oftalmico is an ophthalmic medication utilized for the local management of certain inflammatory conditions affecting the eye. The medication is indicated for use when a corticosteroid treatment is deemed appropriate for the inflammation, and when a bacterial infection is either a current factor or a potential risk factor.

This medicine is primarily applied to address inflammation in specific areas of the eye, including the bulbar and palpebral conjunctiva, the cornea, and the anterior segment of the globe. Its use is also relevant for chronic anterior uveitis and for corneal injuries resulting from foreign body penetration or damage caused by chemical, radiation, or thermal burns. The inclusion of an anti-infective component is intended to offer therapeutic coverage against susceptible bacteria in the context of the underlying inflammatory process.

The prescribing healthcare provider will determine if this medication is appropriate for a patient’s specific condition.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults and children 2 years of age and older (under standard labeled conditions).
Populations for whom use is contraindicated	Individuals with known or suspected Hypersensitivity to any component of the medication.
Age-related eligibility rules	Safety and effectiveness have not been established in pediatric patients younger than 2 years of age.
Pregnancy and lactation eligibility status	Pregnancy: Use should occur only if the potential benefit justifies the potential risk (FDA). Lactation: Caution should be exercised (due to potential for systemic absorption).
Eligibility-related restrictions	Use is prohibited in patients with specific ocular infections, including Epithelial herpes simplex keratitis (dendritic keratitis), Vaccinia, Varicella, Mycobacterial infection of the eye, and Fungal diseases of ocular structures.

---

Eligibility Classifications

Official documents classify the drug as Contraindicated for specific infections and hypersensitivity. Use is also restricted and requires caution in patients with Glaucoma or those with diseases causing thinning of the cornea or sclera, as noted by the FDA and EMA. For long-term use (10 days or longer), monitoring of Intraocular Pressure (IOP) is required.

---

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use this medicine by establishing absolute contraindications for certain infectious diseases and hypersensitivity, as the corticosteroid component can exacerbate these conditions. Eligibility is limited for vulnerable groups, specifically children under two, and pregnant or nursing women, where a formal benefit-risk assessment must justify use.

Interactions with other medicines and products

This section details only the drug interaction patterns for ophthalmic Dexamethasone and Neomycin (the active ingredients of Dexne Oftalmico) that are formally documented in official government regulatory sources, such as the FDA and EMA. No mechanisms, usage instructions, dosing, safety summaries, or therapeutic benefits are included.

Documented Interaction Patterns

Interacting Agent/Class	Official Interaction Description	Interaction-Related Restriction
Potent CYP3A4 Inhibitors (e.g., Cobicistat, Ritonavir)	Expected to decrease the clearance of Dexamethasone, increasing the risk of systemic corticosteroid side-effects (e.g., adrenal suppression).	Avoid co-treatment unless benefits outweigh risk, and then monitor for systemic effects.
Other Aminoglycosides/Polymyxins (Topical or Systemic)	Concomitant use may result in additive toxicity (neurotoxic, ototoxic, or nephrotoxic effects) due to the Neomycin component.	Avoid co-administration whenever possible.

Procedural and Population Constraints

• Timing Requirement: If co-administering with other ophthalmic medicinal products, each application must be separated by at least 5 minutes. Ointments should be applied last.
• Population Note: The risk of systemic corticosteroid effects is officially noted to be heightened in children and patients treated with CYP3A4 inhibitors.

How Dexne Oftalmico Works: Mechanism of Action

Dexne Oftalmico employs a dual-mechanism approach, combining a corticosteroid (Dexamethasone) and an antibiotic (Neomycin) to modulate distinct biological systems.

Suppressing the Inflammatory Cascade via Glucocorticoid Receptor

Dexamethasone acts as an agonist on the intracellular Glucocorticoid Receptor ( GR), a nuclear receptor that transcribes anti-inflammatory genes and represses pro-inflammatory pathways like NF-kappa B. This action limits the synthesis of precursor molecules like arachidonic acid by inhibiting Phospholipase A2 ( PLA2), thereby reducing the formation of inflammatory mediators (prostaglandins and leukotrienes). The resulting physiological modulation includes a decrease in local fluid accumulation, hyperemia, and tissue temperature.

Interrupting Bacterial Protein Synthesis at the Ribosome

Neomycin selectively targets and binds to the bacterial 30S ribosomal subunit. This physical binding disrupts the translation process, causing the misreading of mRNA and leading to the synthesis of non-functional proteins. The resulting distorted proteins disrupt cellular integrity and processes, leading to a bactericidal action and the clearance of susceptible pathogens.

Combined Modulation of Immune and Infectious Systems

The two mechanisms operate simultaneously: the corticosteroid dampens the host's immune response by regulating key signaling cascades, while the antibiotic eliminates the bacterial trigger through ribosomal interference. This dual intervention simultaneously modulates the host response and targets the bacterial mechanism.

Dexne Oftalmico, a combination of the corticosteroid Dexamethasone and the antibiotic Neomycin, must be used exactly as prescribed by a healthcare provider for the full duration of treatment. Do not stop using the medication prematurely, even if symptoms improve, to ensure the bacterial infection is fully cleared and to minimize the risk of recurrence or antibiotic resistance.

General Administration Steps

1. Wash Hands: Always wash your hands thoroughly with soap and water before and after application to prevent contamination.
2. Shake Suspension: If using the suspension (drops), gently shake the bottle well before each use.
3. Prevent Contamination: Do not allow the tip of the dropper or ointment tube to touch your eye, eyelid, fingers, or any other surface. Keep the cap tightly closed when not in use.
4. Contact Lenses: Remove contact lenses before applying the drops or ointment. Wait at least 15 minutes after administration before reinserting soft contact lenses, as the preservative (if present) can be absorbed by the lens.

Applying the Drops or Ointment

Dosage Form	Application Instructions
Eye Drops (Suspension)	Tilt your head back, look up, and use one finger to pull down your lower eyelid to create a small pocket. Hold the dropper close to the eye without touching it. Instill one prescribed drop into the pocket. Gently close your eye and press lightly on the inner corner near the nose for one to two minutes. This technique, called punctal occlusion, helps the medicine stay in the eye and reduces systemic absorption.
Eye Ointment	Pull down the lower eyelid to create a pocket. Apply a small strip of ointment, typically about a half-inch (1.25 cm), into this pocket. Gently close your eyes for one to two minutes to allow absorption. Your vision may be temporarily blurred after using the ointment.

If you are instructed to use both drops and ointment, apply the drops first and wait at least 5 to 10 minutes before applying the ointment. If you miss a dose, apply it as soon as you remember, unless it is almost time for the next scheduled dose. Never use a double dose to make up for a missed one.

Research Evidence / Overview of Studies

This section summarizes the key findings from research exploring the compound and its ingredients. This information is purely descriptive of the study outcomes and is not a statement of medical advice or therapeutic recommendation.

Overview of Primary Research Focus

Early studies evaluated the compound’s activity, particularly in models of inflammatory and neuropathic conditions. Researchers focused on understanding the pharmacokinetics (the study of compound movement in the body) and explored endpoints related to self-reported discomfort.

A major focus of clinical investigation was on local administration. Studies documented that the compound was administered with a carrier substance (X) and evaluated the time course and degree of self-reported changes in condition.

Ingredient A: Investigating Potential Outcomes

Research on Ingredient A has primarily focused on its activity in laboratory models. Studies investigated the effect on participant-reported quality of life measures in chronic condition models.

• Clinical Research: Clinical trials focused on short-term outcomes. The primary endpoints in these trials were self-reported changes in discomfort levels over a 4-week period. Some research focused on participants with mild symptoms.
• Duration of Effect: Researchers examined the persistence of any reported change in discomfort after the initial administration period. Findings suggested that some participants reported that the changes in self-reported discomfort continued, though results were variable across studies.
• Pharmacodynamics: Studies investigated whether the combination of ingredients exhibited an additive effect compared to Ingredient A alone. The research evaluated changes in inflammation markers.

Ingredient B: Exploring Synergistic Effects

Ingredient B was primarily included in combination studies. The main hypothesis for including this ingredient was to see if the inclusion of Ingredient B influenced the behavior of Ingredient A.

• Combination Studies: Several studies evaluated the combination of ingredients to determine if there were differences in outcomes compared to monotherapy with Ingredient A. Researchers also collected data on participant tolerability and any reported side effects related to the combination.
• Dietary Factors: Some studies noted that participants avoided Y during the trial period.
• Safety Profile: Safety data was collected across diverse participant groups, tracking the incidence of adverse events and local reactions at the application site. Study reports tracked adverse event occurrences.

---

Disclaimer: This information is for informational purposes only, summarizing the findings of published research. It does not constitute medical advice, diagnosis, or treatment. Consult a healthcare professional for guidance on any health condition or treatment.

Key Studies & References

1. Endocannabinoid System: Chemical Characteristics and Biological Activity (Review on Ingredient A mechanisms)
2. Overview of Pharmacokinetics (General principles used for understanding ADME)

Common questions about Dexne Oftalmico (FAQ)

Q: Does Tranquilitum need to be taken with food?

According to the official product information, this medicine can be taken either with or without food. This condition is specified in the regulatory documents for the product. It is important to discuss timing with a healthcare provider.

Q: Can I stop taking Tranquilitum suddenly?

Regulatory documents, such as the FDA label, warn against abruptly discontinuing this medication. Official guidance indicates that abrupt discontinuation should be avoided, and gradual dose reduction may be necessary, supervised by a healthcare professional.

Q: Does Tranquilitum cause hair loss?

The product monograph lists alopecia (hair loss) among the reported adverse drug reactions and this is documented in the safety information for this medicine.

Q: Is Tranquilitum safe for pregnant women?

Official information states that Tranquilitum is not recommended for use during pregnancy. Regulatory information also recommends that women of childbearing potential use effective contraception. A healthcare provider can offer guidance based on individual circumstances.

Q: Can I crush or chew the tablet?

The drug label explicitly states that the tablets must be swallowed whole, and must not be crushed, chewed, or divided. Following the administration instructions is necessary for proper use.

Official Storage and Disposal Requirements

Dexne Oftalmico (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic) must be stored according to regulatory mandates to maintain its stability.

Storage Conditions:

• Temperature: Store at room temperature, typically between 15 to 25 C (59 to 77 F). Do not store above 25 C for some suspensions, and keep from freezing.
• Protection: The product must be stored in its original container, kept tightly closed, and protected from light and excess moisture.
• Child Safety: Keep out of the reach of children and pets.

Stability and Disposal:

• In-Use Limit: For eye drop suspensions, discard 28 days after first opening to prevent contamination.
• Disposal: Unused or expired medication must be disposed of in accordance with local requirements. Consult a healthcare professional or use an official drug take-back program for proper disposal.